Extensively drug-resistant tuberculosis: new strains, new challenges

References

• World Health Organization. Report of the Meeting of the WHO Global Task Force on XDR-TB. Geneva, Switzerland (2006).
   Google Scholar
• Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs wordwide, 2000–2004. MMWR55, 301–305 (2006).
   PubMedGoogle Scholar
• World Health Organization. Anti-Tuberculosis Drug Resistance in the World (Fourth Report). WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva, Switzerland 2002–2007. (2008).
   Google Scholar
• Extensively drug-resistant tuberculosis – United States, 1993–2006. MMWR56, 250–253 (2007).
   PubMedGoogle Scholar
• Banerjee R, Allen J, Westenhouse J et al. Extensively drug resistant tuberculosis (XDR TB) in California, 1993–2006. Clin. Infec. Dis.47, 450–457 (2008).
   PubMed Web of Science ®Google Scholar
• Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int. J. Tuberc. Lung Dis.12, 99–104 (2008).
   PubMed Web of Science ®Google Scholar
• Cox HS, Kalon S, Allamuratova S et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR TB among treatment failures. PLoS ONE (11), e1126 (2007).
   PubMedGoogle Scholar
• Toungoussova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur. J. Clin. Microbiol. Infect. Dis24, 202–206 (2005).
   PubMedGoogle Scholar
• Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis.5, 887–893 (2001).
   PubMed Web of Science ®Google Scholar
• Young DB, Perkins MD, Duncan K, Barry CE III. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest.118, 1255–1265 (2008).
   PubMed Web of Science ®Google Scholar
• Basu S, Galvani AP. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. Epidemiol. Infect.1–14 (2008).
   Google Scholar
• Chaisson RE, Martinson NA. Tuberculosis in Africa – combating an HIV driven crisis. NEJM358, 1089–1092 (1089).
   Google Scholar
• Jeon CY, Hwang SH, Min JH et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis.46, 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995–2002, after the implementation of DOTS-Plus. Int. J. Tuberc. Lung Dis.8, 760–766 (2004).
   PubMedGoogle Scholar
• Pillay M, Sturm AW. Evolution of extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis.45, 1409–1414 (2007).
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet,368, 1575–1580 (2006).
   PubMed Web of Science ®Google Scholar
• Masjedi MR, Farnia P, Sorooch S et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin. Infect. Dis.43, 841–847 (2006).
   PubMed Web of Science ®Google Scholar
• Dahle UR. Extensively drug resistant tuberculosis: beware patients lost to follow-up. BMJ333, 705 (2006).
   PubMedGoogle Scholar
• Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog.2, e61 (2006).
   PubMed Web of Science ®Google Scholar
• Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science312, 1944–1946 (2006).
   PubMed Web of Science ®Google Scholar
• Blower SM, Chou T. Modeling the emergence of the “hot zones”: tuberculosis and the amplification dynamics of drug resistance. Nat Med.10, 1111–1116 (2004).
   PubMed Web of Science ®Google Scholar
• Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect. Dis.7, 443 (2007).
   PubMed Web of Science ®Google Scholar
• Basu S, Andrews JR, Poolman EM et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet,370, 1500–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Porco TC, Getz WM. Controlling extensively drug-resistant tuberculosis. Lancet370, 1464–1465 (2007).
   PubMedGoogle Scholar
• Migliori BB, Ortmann J, Girardi E et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg. Infect. Dis.13, 780–781 (2007).
   PubMed Web of Science ®Google Scholar
• Migliori GB, Besozzi G, Girardi E et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J.30, 623–626 (2007).
   PubMed Web of Science ®Google Scholar
• Kim H-R, Hwang SS, Kim HJ et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis.45, 1290–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Girardi E et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis. Eur. Respir. J.31, 904–910 (2008).
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Centis R et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J.31, 1155–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Blaas SH, Mutterlein R, Weig J et al. Extensively drug-resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect. Dis.8, 60 (2008).
   PubMedGoogle Scholar
• Cain KP, Benoit SR, Winston CA, MacKenzie WR. Tuberculosis among foreign-born persons in the United States. JAMA300, 405–412 (2008).
   PubMed Web of Science ®Google Scholar
• Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents. Chemother.46, 267–274 (2002).
   PubMed Web of Science ®Google Scholar
• Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin. Micro. Rev.19, 558–570 (2006).
   PubMed Web of Science ®Google Scholar
• Riska PF, Jacobs WR, Alland D. Molecular determinants of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis.4, S4–S10 (2000).
   PubMedGoogle Scholar
• Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet13, 647–650 (1993).
   Google Scholar
• Williams DL, Waguespack C, Eisenach K et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother.38, 2380–2386 (1994).
   PubMed Web of Science ®Google Scholar
• Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother.48, 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Wang J-Y, Lee L-N, Lai H-C et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother.59, 860–865 (2007).
   PubMedGoogle Scholar
• Maus C, Plikaytis B, Shinnick T. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother.49, 3192–3197 (2005).
   PubMed Web of Science ®Google Scholar
• Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob. Agents. Chemother.40, 1186–1188 (1996).
   PubMed Web of Science ®Google Scholar
• Gegia M, Mdivani N, Mendes RE et al. Prevalence of and molecular basis for tuberculosis drug resistance in the republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrob. Agents Chemother.52, 725–729 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto S, Tamaru A, Nakajima C et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol. Microb.63, 1096–1106 (2007).
   PubMed Web of Science ®Google Scholar
• Alangaden G, Kreiswirth B, Aouad A et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother.42, 1295–1297 (1998).
   PubMed Web of Science ®Google Scholar
• Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother.47, 2971–2973 (2003).
   PubMed Web of Science ®Google Scholar
• Maus CE, Plikaytis BB, Shinnick TM. Mutation of the tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents. Chemother.49, 571–577 (2005).
   PubMed Web of Science ®Google Scholar
• Shin SS, Yagui M, Ascencios L et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg. Infect. Dis.14, 701–708 (2008).
   PubMedGoogle Scholar
• Yagui M, Perales MT, Asencios L et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int. J. Tuberc. Lung Dis.10, 838–843 (2006).
   PubMedGoogle Scholar
• Kim SJ, Espinal MA, Abe C et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int. J. Tuberc. Lung Dis.8, 1157–1158 (2004).
   PubMed Web of Science ®Google Scholar
• Pfyffer GE, Bonata DA, Ebrahmizadeh A et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC460 technique and the proportion method with solid media. J. Clin. Microbiol.37, 3179–3186 (1999).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus. WHO/CDS/TB/2001.288 (2001).
   Google Scholar
• Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol.44, 811–818 (2006).
   PubMed Web of Science ®Google Scholar
• Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol.44, 688–692 (2006).
   PubMed Web of Science ®Google Scholar
• Sanders CA, Nieda RR, Desmond EP. Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and VACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J. Clin. Microbiol.42, 5225–5228 (2004).
   PubMedGoogle Scholar
• Fattorini L, Iona E, Cirillo D et al. External quality control of Mycobacterium tuberculosis drug susceptibility testing: results of two rounds in endemic countries. Int. J. Tuberc. Lung Dis.12, 214–217 (2008).
   PubMedGoogle Scholar
• Laszlo A, Rahman M, Espinal M, Raviglione M et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational reference laboratory network: five rounds of proficiency testing, 1994–1998. Int. J. Tuberc. Lung Dis.6, 748–756 (2002).
   PubMedGoogle Scholar
• Cooksey RC, Morlock GP, Glickman S, Crawford JT. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J. Clin. Microbiol.35, 1281–1283 (1997).
   PubMed Web of Science ®Google Scholar
• Lin SYG, Probert W, Lo M, Desmond E. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex form cultures or smear-positive sputa by use of molecular beacons. J. Clin. Microbiol.42, 4204–4208 (2004).
   PubMed Web of Science ®Google Scholar
• Piatek AS, Tyagi S, Pol AC et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat. Biotechnol.16, 359–363 (1998).
   PubMed Web of Science ®Google Scholar
• Andrews JR, Shah NS, Gandhi N, Moll R, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J. Infect. Dis.196, S482–S490 (2007).
   PubMed Web of Science ®Google Scholar
• Seagar A-L, Prendergast C, Emmanuel FX, Rayner A, Thomson S, Laurenson IF. Evaluation of the GenoType Mycobacteria Direct assay for the simultaneous detection of the Mycobacterium tuberculosis complex and four atypical mycobacterial species in smear-positive respiratory specimens. J. Med. Microbiol.57, 605–611 (2008).
   PubMedGoogle Scholar
• Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med.177, 787–792 (2008).
   PubMed Web of Science ®Google Scholar
• Quezada CM, Kamazi E, Mukamutara J et al. Implementation validation performed in Rwanda to determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries. J. Clin. Microbiol.45, 3111–3114 (2007).
   PubMed Web of Science ®Google Scholar
• Fhogartaigh CJN, Vargas-Prada S, Huancare V, Lopez L, Rodrigues J, Moore DAJ. Physician-initiated courtesy MODS testing for TB and MDR-TB diagnosis and patient management. Int. J. Tuberc. Lung Dis.12, 555–560 (2008).
   PubMedGoogle Scholar
• Moore DAJ, Evans CAW, Gilman RH et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Eng. J. Med.355, 1539–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Arias M, Mello FCQ, Pavon A et al. Clinical evaluation of the microscopic observation drug-susceptibility assay for detection of tuberculosis. Clin. Infect. Dis.44, 674–680 (2007).
   PubMedGoogle Scholar
• Shiferaw G, Woldeamanuel Y, Gebeyehu M, Girmachew F, Demessie D, Lemma E. Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol.45, 1093–1097 (2007).
   PubMed Web of Science ®Google Scholar
• Tovar M, Siednaer MJ, Gilman RH et al. Improved diagnosis of pleural tuberculosis using the microscopic-observation drug susceptibility technique. Clin. Infect. Dis.46, 909–912 (2008).
   PubMed Web of Science ®Google Scholar
• Caws M, Ha DTM, Torok E et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS ONE2, e1173 (2007).
   PubMedGoogle Scholar
• Pai M, Kalantri SP. Bacteriophage-based tests for tuberculosis. Indian J. Med. Microbiol.23, 149–150 (2005).
   PubMedGoogle Scholar
• Kalantri SP, Pai M, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta-analysis. BMC Infect. Dis.5, 59 (2005).
   PubMed Web of Science ®Google Scholar
• Pai M, Kalantri S, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampin resistance in Mycobacterium tuberculosis: a meta-analysis. J. Infect.51, 175–187 (2005).
   PubMed Web of Science ®Google Scholar
• Traore H, Ogwang S, Mallard K et al. Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Ann. Clin. Microbiol. Antimicrob.6, 1 (2007).
   PubMedGoogle Scholar
• World Health Organization. The Global MDR-TB and XDR-TB Response Plan 2007–2008. WHO/Stop TB Partnership, Geneva, Switzerland (2007).
   Google Scholar
• Drobniewski FA, Hoffner S, Rusch-Gerdees S, Skenders G, Thomsen V et al. Recommended standards for modern tuberculosis laboratory services in Europe. Eur. Respir. J.28, 903–909 (2006).
   PubMed Web of Science ®Google Scholar
• Mukherjee JS, Rich ML, Socci AR et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet363, 474–481 (2004).
   PubMed Web of Science ®Google Scholar
• Treatment of Tuberculosis, American Thoracic Society, Center for Disease Control and Prevention, and Infectious Diseases Society of America. MMWR52, RR-11 (2003).
   Google Scholar
• Iseman MD. Treatment of multidrug-resistant tuberculosis N. Eng. J. Med.329, 784–791 (1993).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland (2006).
   Google Scholar
• Iseman MD. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosisAm. Rev. Respir. Dis.141, 623–625 (1990).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kang CH, Kim YT et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur. Respir. J.28, 576–580 (2006).
   PubMed Web of Science ®Google Scholar
• Kwon YS, Kim YH, Suh GY et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis.47, 496–502 (2008).
   PubMed Web of Science ®Google Scholar
• Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.6, 143–149 (2002).
   PubMedGoogle Scholar
• Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J. Thorac. Cardiovasc. Surg.121, 448–453 (2001).
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J. Thorac Cardiovasc Surg.128, 523–528 (2004).
   PubMed Web of Science ®Google Scholar
• Somocurcio JG, Sotomayor A, Shin S et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax62, 416–421 (2007).
   PubMed Web of Science ®Google Scholar
• Mitnick C, Bayona J, PAlacios E. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Eng. J. Med.348, 119–128 (2003).
   PubMed Web of Science ®Google Scholar
• Nathanson E, Weezenbeek CL-V, Rich ML et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis.12, 1389–1397 (2006).
   PubMed Web of Science ®Google Scholar
• Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus program in Latvia. Int. J. Tuberc. Lung Dis.11, 585–587 (2007).
   PubMedGoogle Scholar
• Francis J Curry National Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: a Survival Guide for Clinicians (2nd Edition). 39 (2008).
   Google Scholar
• Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med.169, 1103–1109 (2004).
   PubMed Web of Science ®Google Scholar
• Gosling RD, Uiso LO, Sam NE et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168, 1342–1345 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.10, 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Pletz MWR, DeRoux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother.48, 780–782 (2004).
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.12, 128–138 (2008).
   PubMed Web of Science ®Google Scholar
• Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis.196, S28–S34 (2007).
   PubMedGoogle Scholar
• Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med.4, e292 (2007).
   PubMed Web of Science ®Google Scholar
• Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J. Chemother.17, 169–173 (2005).
   PubMed Web of Science ®Google Scholar
• McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis.196, S63–S75 (2007).
   PubMed Web of Science ®Google Scholar
• Chung W-S, Chang Y-C, Yang M-C. Factors influencing the successful treatment of infectious pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.11, 59–64 (2007).
   PubMedGoogle Scholar
• Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Eng. J. Med.330, 1179–1184 (1994).
   PubMed Web of Science ®Google Scholar
• Peloquin C. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs62, 2169–2183 (2002).
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR49(RR06), 1–54 (2000).
   PubMedGoogle Scholar
• Villarino ME, Dooley SW, Geiter LJ, Castro KG, Snider DE. Management of persons exposed to multidrug-resistant tuberculosis. MMWR41(RR-11), 59–71 (1992).
   Google Scholar
• Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect. Dis.8, 359–368 (2008).
   PubMed Web of Science ®Google Scholar
• Enarson D, Arnadottir T, Trebucq A. Management of Tuberculosis: a Guide for Low Income Countries (5th Edition). International Union Against Tuberculosis and Lung Disease, Paris, France (2000)
   Google Scholar
• Fair E, Hopewell PC, Pai M. International standards for tuberculosis care: revisiting the cornerstones of tuberculosis care and control. Expert Rev. Anti Infect. Ther.5, 61–65 (2007).
   PubMed Web of Science ®Google Scholar
• Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic? Eur. Respir. J.29, 423–427 (2007).
   PubMed Web of Science ®Google Scholar
• Raviglione MC, Uplekar MW. WHO’s new Stop TB strategy. Lancet367, 952–955 (2006).
   PubMed Web of Science ®Google Scholar